Medications for Plaque Psoriasis
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Plaque Psoriasis.
Found 25 Approved Drugs for Plaque Psoriasis
Ustekinumab
Brand Names
Steqeyma, Pyzchiva, Stelara, Ustekinumab-TTWE, Yesintek, Wezlana, Otulfi, Imuldosa
Ustekinumab
Brand Names
Steqeyma, Pyzchiva, Stelara, Ustekinumab-TTWE, Yesintek, Wezlana, Otulfi, Imuldosa
Form: Injection, Solution
Method of administration: Subcutaneous, Intravenous
FDA approval date: September 25, 2009
Classification: Interleukin-12 Antagonist
PYZCHIVA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy.
Adalimumab
Brand Names
Adalimumab-aacf, Humira
Adalimumab
Brand Names
Adalimumab-aacf, Humira
Form: Kit
Method of administration: Subcutaneous
FDA approval date: December 31, 2002
HUMIRA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis.
Cosentyx
Generic Name
Secukinumab
Cosentyx
Generic Name
Secukinumab
Form: Injection
Method of administration: Subcutaneous, Intravenous
FDA approval date: January 21, 2015
Classification: Interleukin-17A Antagonist
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in patients 6 years and older who are candidates for systemic therapy or phototherapy.
Infliximab
Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
Infliximab
Brand Names
Zymfentra, Avsola, Inflectra, Remicade, Renflexis
Form: Injection, Kit
Method of administration: Subcutaneous, Intravenous
FDA approval date: August 24, 1998
Classification: Tumor Necrosis Factor Blocker
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following treatment with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. moderately to severely active Crohn's disease following treatment with an infliximab product administered intravetnously.
Showing 1-5 of 25
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances